BBNX · Beta Bionics, Inc.
$19.01
+0.06 (+0.32%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$873.25M
Shares
44.99M
Volume · Oct 5
624.63K
Avg daily vol (3M)
1.28M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$18.95
Open$18.91
Day$18.74–19.27
52W close$8.86–31.99
Avg vol 30d1.3M
Short int10.6M · 23.6% float · 9.9d
Short vol50%
Last earningsJul 29, 2026
DataJan 2025–Oct 2026
Filing10-Q · Jul 29
Up next
Next earnings call
Nov 1, 2026
Est · unconfirmed
· in 4 wks
filed Jul 29, 2026
call held Apr 21, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$119.01M
Trailing 12 months
Net income (TTM)
−$72.97M
Trailing 12 months
Revenue growth YoY
+37.8%
Year over year
Operating margin
-69.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-7.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$180.49M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.7%
Year over year · more shares
Price change (1Y)
-7.5%
Trailing year
Short interest
23.6%
Latest settlement · 9.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+20%
above
Price vs 50-day avg
+3%
above
RSI (14)
46
neutral
MACD trend
Negative
52-week position
44%
mid-range
Momentum
relative strength
1-month return
−2%
trailing
6-month return
+60%
trailing
YTD return
−38%
this year
Relative strength
+49%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $18 › 200d $16 — 50d above 200d
Institutional flow
Flat
1 of 136 funds reported for Sep 30 · net 0 sh shares
Insider flow
Distributing
Net -$723.1K over 90 days · 100% sells
Short interest
Rising
23.60% of float · ▲ +12.9% MoM · 9.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
136 holders — mid 1-yr range
Squeeze score
86
high risk · 0–100
Fundamentals
Revenue growth
+54%
Y/Y
Gross margin
55%
expanding
EPS growth
+79%
Y/Y
Free cash flow
$-56.2M
Quant / Vol
risk profile
Volatility
83%
annualized · 1-yr
Max drawdown
−72%
past year
ATR
6.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 29, 2026
Estimated total revenue
· full year 2026
Initiated
$131M – $136M
prior FY $100.25M
midpoint +33.2% Y/Y
Estimated new patient starts reimbursed through the PBP channel
· full year 2026
Initiated
37% – 39%
Estimated gross margin
· full year 2026
Initiated
58.5% – 59.5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+20%
Bullish
Price vs 50-day avg
+3%
Bullish
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
44%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $18 › 200d $16 — 50d above 200d
Institutional flow
Flat
1 of 136 funds reported for Sep 30 · net 0 sh shares
Insider flow
Distributing
Net -$723.1K over 90 days · 100% sells
Short interest
Rising
23.60% of float · ▲ +12.9% MoM · 9.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
136 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $9
Now $19 · 44%
Range high $32
vs 200-day avg +20%
vs 50-day avg +3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BBNX
this stock
Beta Bionics, Inc.
|
$873.25M | -37.8% | +53.9% | — | 23.6% |
|
ABT
Abbott Laboratories
|
$174.90B | -20.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -8.4% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -18.8% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.5% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BBNX | -7.7% | -2.4% | +60.5% | -0.2% | -37.8% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -8.9% | -3.0% | +48.9% | -1.8% | -51.4% |